Severe Ileocolonic Crohn's Disease Flare Associated with Fecal Microbiota Transplantation Requiring Diverting Ileostomy

Vivy Tran, MD 1, Jennifer Phan, MD 2, Benjamin Nulsen, MD 2, Lizhou Huang, MD 2, Marc Kaneshiro, MD 2, Guy Weiss, MD 2, Wendy Ho, MD 2, Jonathan Sack, MD 2, Christina Ha, MD 3, Daniel Uslan, MD 4, and Jenny S. Sauk, MD 2,5

1Department of Internal Medicine, University of California Los Angeles, Los Angeles, California
2Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles, Los Angeles, California
3Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California
4Division of Infectious Diseases, University of California Los Angeles, Los Angeles, California
5Center for Inflammatory Bowel Diseases, University of California Los Angeles, Los Angeles, California

ABSTRACT

Patients with inflammatory bowel disease (IBD) are at increased risk of developing Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) is an effective therapy with a high success rate in preventing recurrent CDI. However, patients with IBD have decreased response to FMT for recurrent CDI, with several reports also suggesting potential IBD flare post-FMT. We present a case of mild ileocolonic Crohn's disease in a patient treated with FMT for recurrent CDI who subsequently developed severe steroid-refractory flare requiring surgical intervention 1 week post-FMT. Greater understanding of risk factors associated with post-FMT IBD flare is indicated.

INTRODUCTION

Fecal microbiota transplantation (FMT) involves transplantation of feces from a healthy individual to another to introduce a complex, diverse community of intestinal microbes to the recipient. The intestinal microbiome of a patient with recurrent Clostridium difficile infection (CDI) shows decreased microbial diversity, with antibiotic treatment considered the most commonly known risk factor associated with CDI development. Multiple CDI recurrences are associated with increasing loss of microbial diversity.1 Studies show that FMT has a roughly 90% success rate in preventing recurrence of CDI.2

Inflammatory bowel disease (IBD) and other systemic inflammatory conditions are also associated with disruption in the gut microbial ecosystem. Success of FMT in CDI has inspired studies to explore FMT in conditions such as IBD. While the pathophysiology of IBD still remains largely unknown, genetically susceptible individuals are thought to experience an altered immune response to commensal flora or other environmental factors leading to gastrointestinal inflammation, microbial dysbiosis, and a further decrease in microbial diversity.3 Several studies have suggested that repeat administration of FMT can potentially decrease intestinal inflammation in ulcerative colitis.4 However, FMT has not shown consistent success in preventing recurrent CDI in patients with IBD or treating the IBD itself.5 Preliminary reports suggest that up to 25% of IBD patients can also experience IBD flare post-FMT.6
CASE REPORT

A 35-year-old man with a history of refractory ileocolonic Crohn’s disease with primary sclerosing cholangitis and recurrent CDI presented with watery diarrhea and abdominal pain. His medical history included refractory Crohn’s disease, first diagnosed at age 28, requiring multiple diverting ileostomies complicated by disease flare upon ileostomy takedown and non-response to multiple therapies, including thiopurines, methotrexate, infliximab, adalimumab, and vedolizumab. Despite counseling, the patient was not amenable to colectomy throughout his disease course. His disease course had been complicated by at least 7 episodes of CDI with positive C. difficile polymerase chain reaction (PCR) tests over the past 7 years corresponding to worsening of clinical symptoms, ultimately requiring long courses of suppressive antibiotic therapy with vancomycin and consideration for FMT in the past. He had negative C. difficile PCR studies between episodes.

Four months prior to this presentation, the patient was on ustekinumab maintenance therapy every 8 weeks with colonoscopy demonstrating mucosal healing and no histological evidence of active disease. An ileostomy takedown was performed at this time (Figure 1). Subsequent colonoscopy 2 months after takedown revealed mild colonic recurrence with few scattered aphthous ulcers noted in the sigmoid and descending colon; biopsies showed only mild histologic activity in the rectum. During this month, he also had an episode of CDI (positive C. difficile PCR) that was subsequently treated with oral vancomycin.

Two months later, the patient had mild tenderness in the lower abdomen. He was afebrile with elevated inflammatory markers (C-reactive protein 2.2 mg/dL; erythrocyte sedimentation rate 35 mm/hr), and C. difficile PCR and stool bacterial pathogens studies were negative. With the intention to prevent future CDI recurrences after his recent episode and history of recurrent 7 prior episodes, FMT was performed via colonoscopy, which revealed mild pancolitis (Figure 2). He received ustekinumab the night following the FMT, which was four weeks after his previous dose, due to evidence of recurrent disease despite standard ustekinumab dosing.

Two days later, the patient was readmitted with fever, abdominal pain, and frequent bloody stools. C-reactive protein and erythrocyte sedimentation rate were elevated to 12.7 mg/dL and 58 mm/hr, respectively. Stool studies were negative for infection. Sigmoidoscopy 1 week after FMT demonstrated punched-out ulcerations in the sigmoid and descending colon (Figure 3). Biopsies for cytomegalovirus were negative. Albumin decreased from 4.0 g/dL on presentation to 2.1 g/dL. Intravenous solumedrol was given for 5 days with initial improvement, but due to worsening symptoms and continued C-reactive protein elevation upon transition to

Figure 1. Timeline of events surrounding presentation.

Figure 2. Colonoscopy image of colonic mucosa prior to fecal microbiota transplantation.
orally and followed up every 4 weeks to maintain remission after CDI relapse and is currently continuing ustekinumab maintenance therapy every 4 weeks to maintain remission after ileostomy takedown.

DISCUSSION

While FMT has demonstrated efficacy in preventing recurrence of CDI, studies are ongoing to evaluate the success of FMT for underlying IBD. Several reports also suggest potential worsening of disease activity after FMT. It is postulated that exposure to microbiota in these IBD patients with altered mucosal integrity promotes a disproportionate host immune response to the transplanted microbiota, resulting in worsening of IBD activity and disease progression. Case reports suggest that greater underlying disease severity may predispose to disease flare post-FMT. Our patient notably had only mild mucosal disease prior to FMT. A similar case described a patient with quiescent ulcerative colitis for more than 20 years who developed a flare of ulcerative colitis after FMT, which was successfully treated with oral steroids.

Potential etiologies of our patient’s rapid flare after FMT were explored. While the passage of unrecognized pathogens in the donor stool may have precipitated his flare, stool studies and biopsies performed were negative for infectious etiologies or cytomegalovirus. While our patient was on immunosuppressive therapy with maintenance ustekinumab escalated to every 4 weeks, multiple studies have demonstrated safe and effective FMT for CDI in immunocompromised patients. It is possible that the flare was impending and occurred coincidentally after the FMT. However, the timing of his acute flare 2 days after FMT, with colonoscopy performed at the time of FMT only showing mild mucosal disease, suggests that the FMT intensified this flare.

Because of the increasing use of FMT for recurrent CDI in patients with IBD, it is important to further understand the effect of this therapy on patients with active and inactive IBD. Prospective studies will help elucidate optimal patient selection and timing of IBD treatment optimization and FMT in patients with IBD. Greater understanding of the risk factors associated with post-FMT IBD flare is also warranted.

DISCLOSURES

Author contributions: V. Tran, J. Phan, B. Nulsen, L. Huang, M. Kaneshiro, G. Weiss, W. Ho, J. Sack, C. Ha, and D. Uslan wrote, edited, reviewed, and approved the final version. JS Sauk wrote, edited, revised, and approved the final version of the manuscript, and she is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received June 17, 2018; Accepted September 12, 2018

REFERENCES

1. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435-48.
2. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial. JAMA. 2017;318(20):1985-93.
3. Qiao YQ, Cai CW, Ran ZH. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered. J Dig Dis. 2016;17(12):800-10.
4. Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: Fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23(10):1702-9.
5. Patel K, Patel A, Hawes D, Shah J, Shah K. Faecal microbiota transplantation: Looking beyond clostridium difficile infection at inflammatory bowel disease. Gastroenterol Hepatol Bed Bench. 2018;11(1):1-8.
6. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the position of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44(5):354-60.
7. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433-8.
8. Newman KM, Rank KM, Vaughn BP, Khoruts A. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes. 2017;8(3):305-9.
9. Alraba S, Jariwala R, Zeitzer K, Montero J. Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised patients: A single-center experience. Transpl Infect Dis. 2017;19(4).
10. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti J. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017;8(6):574-88.
11. Cheng Y, Fischer M. Fecal microbiota transplantation for recurrent or refractory *Clostridium difficile* infection in inflammatory bowel disease. Practical Gastroenterology. 2017;41(1):40-4.
12. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent *Clostridium difficile* infection. Clin Gastroenterol Hepatol. 2013;11(8):1036-38.
13. Mandalia A, Ward A, Tauxe W, Kraft CS, Dhere T. Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for *Clostridium difficile*. Int J Colorectal Dis. 2016;31(5):1059-60.
14. Lukin DJ, Lawlor G, Feathers A, et al. Escalation of therapy in inflammatory bowel disease patients with *Clostridium difficile* infection is associated with better outcomes: An IBD remedy study. Gastroenterology. 2017;152(5):S575.